Abiopharma

News list

TENAX THERAPEUTICS, INC. (TENX)

SEC News
April 22, 2026, 12:00 UTC

(10% Negative) TENAX THERAPEUTICS, INC. (TENX) Announces Delay in roles Trials for Tenax’s evolution Due to Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment Issues, Regulatory Process, Manufacturing Considerations

Full text

News bot April 22, 2026, 12:01 p.m.

📋 TENAX THERAPEUTICS, INC. (TENX) - Clinical Trial Update

Filing Date: 2026-04-22

Accepted: 2026-04-22 08:00:16

Event Type: Clinical Trial Update

Event Details:

TENAX THERAPEUTICS, INC. (TENX) Announces Clinical Trial Update TENAX THERAPEUTICS, INC. (TENX) provided an update on its clinical development programs. Clinical Development Highlights:

Drug Program: roles, experience
Diseases/Conditions: Tenax’s evolution, biotech
Clinical Stage: Phase 3
Update Type: Trial Timeline Adjustment
Primary Factors: Geopolitical Situation, Pandemic-Related Challenges, Patient Enrollment, Regulatory Process
Collaboration: CFO
Updated Timeline: December 2024

🔬 Clinical Development Pipeline (TENAX THERAPEUTICS, INC.):

Product	Type	Development Stage	Therapeutic Area	Source
TNX-103	DRUG	Phase PHASE3	Pulmonary Hypertension Associated With HFpEF	ClinicalTrials.gov
Placebo	DRUG	Phase PHASE3	Pulmonary Hypertension Associated With HFpEF	ClinicalTrials.gov
Levosimendan 2.5 mg/ml Injectable Solution	DRUG	Phase PHASE2	Hypertension Pulmonary Secondary Heart Failure	ClinicalTrials.gov
Matching Placebo	DRUG	Phase PHASE2	Hypertension Pulmonary Secondary	ClinicalTrials.gov
Levosimendan	DRUG	Phase PHASE2	Hypertension Pulmonary Secondary	ClinicalTrials.gov
Normal Saline	DRUG	Phase PHASE2	Traumatic Brain Injury	ClinicalTrials.gov
Oxycyte	DRUG	Phase PHASE2	Traumatic Brain Injury	ClinicalTrials.gov

💼 Business Developments:

Partnership: Not available
Acquisition
Licensing: Not available
Regulatory Approval
Executive Changes: Not available

Structured Data:

Company Name: TENAX THERAPEUTICS, INC.
Ticker Symbol: TENX